Onyx myeloma drug Kyprolis wins FDA approval

The Food and Drug Administration approved Onyx Pharmaceuticals' carfilzomib to treat certain patients with multiple myeloma, the agency said Friday.

Earlier this month, the South San Francisco-based Onyx (NASDAQ: ONXX) began testing carfilzomib, which it calls "Kyprolis," in combination with dexamethasone. The combo is being tested against another treatment, bortezomib, also mixed with dexamethasone.